{'52WeekChange': -0.4102564,
 'SandP52WeekChange': 0.0644362,
 'address1': '411 Hackensack Avenue',
 'address2': 'Suite 501',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.95,
 'askSize': 1800,
 'averageDailyVolume10Day': 433812,
 'averageVolume': 592960,
 'averageVolume10days': 433812,
 'beta': 1.537815,
 'beta3Year': None,
 'bid': 1.84,
 'bidSize': 1400,
 'bookValue': 0.315,
 'category': None,
 'circulatingSupply': None,
 'city': 'Hackensack',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.94,
 'dayLow': 1.83,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.136,
 'enterpriseToRevenue': 1.656,
 'enterpriseValue': 102016672,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.9585714,
 'fiftyTwoWeekHigh': 3.85,
 'fiftyTwoWeekLow': 1.31,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 64586495,
 'forwardEps': -0.09,
 'forwardPE': -20.444445,
 'fromCurrency': None,
 'fullTimeEmployees': 299,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.16834,
 'heldPercentInstitutions': 0.41265,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/rockwellmed.com',
 'longBusinessSummary': 'Rockwell Medical, Inc. operates as a '
                        'biopharmaceutical company that targets end-stage '
                        'renal disease and chronic kidney disease with '
                        'therapies and products for the treatment of iron '
                        'deficiency and hemodialysis. The company offers '
                        'Triferic, an iron therapy that replaces iron and '
                        'maintains hemoglobin in dialysis patients without '
                        'increasing iron stores; and Calcitriol, an active '
                        'vitamin D injection for the management of '
                        'hypocalcemia in patients undergoing chronic '
                        'hemodialysis. It is also developing an intravenous '
                        'formulation of Triferic for use by hemodialysis '
                        'patients. In addition, the company manufactures, '
                        'sells, delivers, and distributes hemodialysis '
                        'concentrates, such as CitraPure citric acid '
                        'concentrate, Dri-Sate dry acid concentrate, RenalPure '
                        'liquid acid concentrate, dry acid concentrate mixer, '
                        'and RenalPure and SteriLyte powder bicarbonate '
                        'concentrate; and ancillary products, including blood '
                        'tubing, fistula needles, dialyzers, drugs, '
                        'specialized component kits, dressings, cleaning '
                        'agents, filtration salts, and other supplies used by '
                        'hemodialysis providers. Its dialysis concentrate '
                        'products are used to maintain human life by removing '
                        'toxins and replacing critical nutrients in the '
                        "dialysis patient's bloodstream. Rockwell Medical, "
                        'Inc. sells its products directly, as well as through '
                        'independent sales agents and distributors. Its target '
                        'customers include senior and operating management of '
                        'dialysis companies, dialysis service providers, '
                        'nephrologists, clinic administrators, nurses, medical '
                        'directors, and technical and purchasing personnel. '
                        'Rockwell Medical, Inc. was founded in 1994 and is '
                        'based in Wixom, Michigan.',
 'longName': 'Rockwell Medical, Inc.',
 'market': 'us_market',
 'marketCap': 127087152,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_378060',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -33433422,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.93,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.14,
 'phone': '248 960 9009',
 'previousClose': 1.95,
 'priceHint': 4,
 'priceToBook': 5.84127,
 'priceToSalesTrailing12Months': 2.0631065,
 'profitMargins': -0.54275,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.94,
 'regularMarketDayLow': 1.83,
 'regularMarketOpen': 1.93,
 'regularMarketPreviousClose': 1.95,
 'regularMarketPrice': 1.93,
 'regularMarketVolume': 251518,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 69069104,
 'sharesPercentSharesOut': 0.083000004,
 'sharesShort': 5732337,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4874514,
 'shortName': 'Rockwell Medical, Inc.',
 'shortPercentOfFloat': 0.1014,
 'shortRatio': 11.04,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'RMTI',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.526,
 'twoHundredDayAverage': 2.3098562,
 'volume': 251518,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.rockwellmed.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '07601'}